Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: A randomised study over 21 months

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Engvall, Inga Lill ^a   Tengstrand, Birgitta ^a   Brismar, Kerstin ^a   Hafström, Ingiäld ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN; BISPHOSPHONIC ACID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEPTIN; METHOTREXATE; SALAZOSULFAPYRIDINE; SOMATOMEDIN C; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; BONE METABOLISM; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INFECTION; MALE; MUSCLE MASS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; ADIPOSE TISSUE; ADULT; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PHOTON ABSORPTIOMETRY; RADIOIMMUNOASSAY;

ABSORPTIOMETRY, PHOTON; ADIPONECTIN; ADIPOSE TISSUE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOLIPOPROTEINS; ARTHRITIS, RHEUMATOID; BODY COMPOSITION; BONE DENSITY; BONE REMODELING; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; MALE; METHOTREXATE; MIDDLE AGED; RADIOIMMUNOASSAY; SULFASALAZINE;

EID: 77958030953     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3169     Document Type: Article

References (56)

1. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004, 43:1219-1223. 10.1093/rheumatology/keh321, 15292530.
2. Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996, 35:309-322. 10.1093/rheumatology/35.4.309, 8624634.
3. Giles JT, Bartlett SJ, Andersen RE, Fontaine KR, Bathon JM. Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum 2008, 59:1407-1415. 10.1002/art.24109, 2670990, 18821641.
4. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002, 40:937-943. 10.1016/S0735-1097(02)02051-X, 12225719.
5. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980 s and 1990s. Ann Rheum Dis 2005, 64:1595-1601. 10.1136/ard.2004.034777, 1755282, 15843450.
6. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res 2004, 12:887-888. 10.1038/oby.2004.107, 15229325.
7. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, . Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202, 11096166, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
8. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006, 84:1463-1472.
9. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, Nevill AM, Panoulas VF, Kita M, Kitas GD. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007, 46:1824-1827. 10.1093/rheumatology/kem291, 18032540.
10. Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol 2008, 27:795-797. 10.1007/s10067-008-0855-7, 18305977.
11. Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008, 35:855-861.
12. Inaba M, Tanaka K, Goto H, Sakai S, Yamada S, Naka H, Imanishi Y, Nishizawa Y. Independent association of increased trunk fat with increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol 2007, 34:290-295.
13. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, Zickert A, Theander J, Thorner A, Hellstrom H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M, Bratt J. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009, 374:459-466. 10.1016/S0140-6736(09)60944-2, 19665644.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
15. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
16. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988, 17:263-271. 10.3109/03009748809098795, 3187457.
17. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995, 854:1-452.
18. Schutz Y, Kyle UU, Pichard C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98 y. Int J Obes Relat Metab Disord 2002, 26:953-960. 10.1038/sj.ijo.0801856, 12080449.
19. Lunar Operator Manual, Expert-XL Software Version 1.7 1998, Madison, MA, USA: Lunar Corporation, Lunar.
20. Abernathy RP, Black DR. Healthy body weights: an alternative perspective. Am J Clin Nutr 1996, 63(3 Suppl):448S-451S.
21. Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW, Lenchik L, Palla SL, Ambrosius WT, Tracy RP, Pahor M. Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr 2005, 82:428-434.
22. Book C, Karlsson MK, Akesson K, Jacobsson LT. Early rheumatoid arthritis and body composition. Rheumatology (Oxford) 2009, 48:1128-1132. 10.1093/rheumatology/kep165, 19602478.
23. Lewiecki EM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S. Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. South Med J 2008, 101:735-739.
24. Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M. Radioimmunoassay of leptin in human plasma. Clin Chem 1996, 42:942-946.
25. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006, 259:493-519. 10.1111/j.1365-2796.2006.01643.x, 16629855.
26. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991, 124:620-629.
27. Hilding A, Brismar K, Degerblad M, Thoren M, Hall K. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995, 80:2646-2652. 10.1210/jc.80.9.2646, 7545695.
28. Littell SAS System for Mixed Models 2006, Cary, NC, USA: SAS Institute Inc, 2, Littell.
29. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783. 10.1038/nri1937, 16998510.
30. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001, 280:E827-E847.
31. Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005, 64:1195-1198. 10.1136/ard.2004.032243, 1755600, 15731289.
32. Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 2009, 36:724-730. 10.3899/jrheum.080626, 19273452.
33. Straub RH, Harle P, Atzeni F, Weidler C, Cutolo M, Sarzi-Puttini P. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol 2005, 32:1253-1258.
34. Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 2008, 582:74-80. 10.1016/j.febslet.2007.11.070, 18054335.
35. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935. 10.1210/jc.86.5.1930, 11344187.
36. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177. 10.1016/S0140-6736(02)08213-2, 11955534.
37. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1213-1218.
38. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 2007, 17:385-390. 10.1007/s10165-007-0605-8, 17929130.
39. Harle P, Sarzi-Puttini P, Cutolo M, Straub RH. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:970-971. 10.1136/ard.2005.040857, 1798194, 16769786.
40. Peters MJ, Watt PH, Cherry L, Welsh P, Henninger E, Dijkmans BA, McInnes IB, Nurmohamed MT, Sattar N. Lack of effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Ann Rheum Dis 2010, 69:1687-1690. 10.1136/ard.2009.114207, 19640853.
41. Nagashima T, Okubo-Fornbacher H, Aoki Y, Kamata Y, Kimura H, Kamimura T, Nara H, Iwamoto M, Yoshio T, Okazaki H, Minota S. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J Rheumatol 2008, 35:936-938.
42. Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jorgensen A, Tarp U, Hetland ML, Horslev-Petersen K, Hornung N, Poulsen JH, Flyvbjerg A, Stengaard-Pedersen K. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol 2009, 36:1885-1891. 10.3899/jrheum.080907, 19684150.
43. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007, 92:571-576. 10.1210/jc.2006-1067, 17119002.
44. Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006, 35:107-111. 10.1080/03009740500474578, 16641043.
45. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006, 33:921-923.
46. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006, 1069:414-419. 10.1196/annals.1351.039, 16855168.
47. Engvall IL, Elkan AC, Tengstrand B, Cederholm T, Brismar K, Hafstrom I. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 2008, 37:321-328. 10.1080/03009740802055984, 18666027.
48. Heszele MF, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology 2004, 145:4803-4805. 10.1210/en.2004-1037, 15489312.
49. McCarthy TL, Centrella M, Canalis E. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 1989, 124:301-309. 10.1210/endo-124-1-301, 2909370.
50. O'Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW. Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol 2008, 252:91-110. 10.1016/j.cellimm.2007.09.010, 2615236, 18325486.
51. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994, 15:80-101.
52. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:353-357. 10.1136/ard.2007.076604, 17644538.
53. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005, 44:1546-1548. 10.1093/rheumatology/kei082, 16263785.
54. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1495-1499. 10.1136/ard.2005.044198, 1798341, 16606653.
55. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996, 11:1531-1538. 10.1002/jbmr.5650111021, 8889854.
56. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999, 14:1614-1621. 10.1359/jbmr.1999.14.9.1614, 10469291.